US3193458A - Method of lowering blood cholesterol level - Google Patents
Method of lowering blood cholesterol level Download PDFInfo
- Publication number
- US3193458A US3193458A US123435A US12343561A US3193458A US 3193458 A US3193458 A US 3193458A US 123435 A US123435 A US 123435A US 12343561 A US12343561 A US 12343561A US 3193458 A US3193458 A US 3193458A
- Authority
- US
- United States
- Prior art keywords
- cholesterol level
- mole
- lowering blood
- blood cholesterol
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
Definitions
- active hypocholesteremic agents in accordance with the present invention can be identified as hydroxyamides of the following formula:
- CoHsCHzCHr 750 45 2 a CoHCHzCHz- 750 35 4 CaH5CH2CHg 1, 000 34: sHn- 750 34 4 7Z-C5Hu 1, 000 49 a
- the LD is the minimum dosage which is lethal to mice upon subcutmcous injection expressed in trig/kg.
- hypocholesteremic effect was evaluated in guinea pigs given 30 rug/kg. orally of the test compound at the beginning of the experiment, 24 hours later, and finally, 48 hours later. Serum cholesterol levels were established at the initiation of the experiment and at 72 hours thereafter, and the percent reduction from the cholesterol level at the initiation of the experiment noted.
- the selected composition of this invention has N-fi-phenethyl glycolamide as its essential active ingredient.
- hypocholesteremic effect be obtained upon oral administration and that the essential active ingredients be substantially without toxicity and that they exert little or no effect in other pharmacological areas at dosage levels consistent with good hypocholesteremic activity.
- the compounds of this invention are active, however, when administered orally, rectally, or parenterally.
- the active ingredients are obtained as distillable oils or low melting solids and are somewhat soluble in water, but for therapeutic use, they are preferably incorporated in suitable pharmaceutical carriers and in use, the compounds are employed in the recommended dosage of 100-1200 mg./day, preferably in doses of 150-300 mg, two or four times a day.
- the formulation should preferably contain 50-500 mg. of active drug per dosage unit.
- the drug was inactive in the following pharmacological tests (30 and 60 mg./kg. orally): anticonvulsant, antitremorine, muscle relaxant, bronchodilator. No central nervous excitatory or depressant activity was observed up to mg/kg. S.C. and 60 mg./kg. orally. It had no local anesthetic action on the guinea pig eye at 20 mg./ml.
- N-(fi-phenethyl)glycolamide was without significant effect on blood pressure, heart rate, or the rate of respiration. It did not modify the response to subsequent injections of adrenaline, acetylcholine or histamine.
- the bromsulfalein test and prothrombin time were normal after 3 days administration.
- the compound had no analgesic effect on testing as high as 250 mg./kg. subcutaneously, but at these substantially higher doses and upon S.C. injection, it had anticonvulsant activity.
- Example 1 N-(fi'-phenethyl) gly colamide
- a mixture of 126 g. (1.03 mole) of [i-phenethylamine and 96 g. (0.924 mole) of ethyl glycolate was heated under reflux for 22 hours.
- a Dean-Stark trap was interposed to remove the formed ethanol (theory 54 ml.).
- 48 ml. of ethanol had been collected and the internal temperature was 145, the residue was cooled and 270 ml. ethyl acetateaddedI
- Example -(lt-amyl) -fl-hydroxypropionamide To a solution of 7.2g. (0.1 mole) of propiolactone in 50 ml. of water cooled to 0-5, there was added 8.7 g. (0.1 mole) n-amylamine over 15 minutes with stirring. Water was removed by vacuum distillation. The residue was stirred with hexane, the hexane removed and the residue (11.9 g.) distilled to give 6.2 g., 13.1 l30-132 (0.5 mm.), n 1.4714.
- Example 6 -N ,G-phnethyl -p-hydr0xy propionamide
- a cooled solution 5 aqueous
- 12.1 g. (0.1 mole) of B-phenethylamine was added dropwise over 15 minutes 7.2 g. (0.1 mole) of freshly distilled 18-propiolactone. After removal of water by vacuum distillation, the residue was distilled to give 10.7 g.,B.P. 180 (.08
- Example 7.-Tdb let formation A granulation is prepared of Lactose V parts 74 Starch do 26 Water, a sufiicient quantity.
- the granulation is dried and screened.
- compositions include coated tablets, capsules, and sustained-release capsules containing 50500 mg; of active ingredient per unit dose.
- the hydroxyarnide is dissolved in about two-thirds of the ethanol and the glyoerinand sorbitol are added.
- the benzoic acid and flavors are dissolved in the balance of the alcohol and combined with the first solution.
- the saccharin and Sucaryl are dissolved in a small amount of the water and coloring agent dissolved therein.'
- the aqueous solution is then added to the alcohol. solution, the balance of the water 'is added to bring the volume to 1 liter and after mixing and filtering an eli'xe'r is obtained containing ,20 mg. of the hydroxy-amide per ml.
- a unit dose of 15 m1. (1 tablespoon) thus contains mg. of the hydroxyamide. 7
- suppositories weighing about 3 g. containing 1503'00 mg. of hydroxyamide.
- any of the hydroxyamides herein characterized as the essential active ingredients may be used, or that a mixture of these amides can be substituted as the active component, and that the amounts of active component can be suitably varied within the range of 50 to 500 rug, and preferably 100 to 400 mg; per dosage unit.
- a method for lowering cholesterol levels which comprises administering to an animal a composition containing as an essential active ingredient a compound conssting of hydroxyamides having the following formula H H(0H)n i1 IR wherein n is an integer from 1-4, and R is selected from the group consisting of C -C alkyl and fl-ph-enethyl, said administration being in amounts sufiicient to substantially reduce the cholesterol level of the blood of the hypercholesteremic animal.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
United States Patent 3,193,458 METHOD OF LOWERING BLOOD CHOLEETEROL LEVEL Seymour L. Shapiro, Hastings on Hudson, and Louis Freedman, Eronxviile, N.Y., assignors to US. Vitamin & Pharmaceutical Corporation, New York, N.Y., a corporation of Delaware No Drawing. Filed .iuly 12, 1961, Ser. No. 123,435 o'Claims. (Cl. 167-65) This invention is concerned with new therapeutic compositions having unusual activity in lowering blood cholesterol levels. More particularly, the invention relates to certain lower hydroxyamides which have hypocholesteremic properties and to the formulation of these amides as therapeutically useful compositions.
The active hypocholesteremic agents in accordance with the present invention can be identified as hydroxyamides of the following formula:
TABLE I.HYPOCHOLESTEREMIC EFFECT min Percent 12 R s.c. in reduction in Mice, cholesterol mgJkg. (72 hrs.) b
1 CoHsCHzCHr 750 45 2 a CoHCHzCHz- 750 35 4 CaH5CH2CHg 1, 000 34: sHn- 750 34 4 7Z-C5Hu 1, 000 49 a The LD is the minimum dosage which is lethal to mice upon subcutmcous injection expressed in trig/kg.
b The hypocholesteremic effect was evaluated in guinea pigs given 30 rug/kg. orally of the test compound at the beginning of the experiment, 24 hours later, and finally, 48 hours later. Serum cholesterol levels were established at the initiation of the experiment and at 72 hours thereafter, and the percent reduction from the cholesterol level at the initiation of the experiment noted.
In particular, the selected composition of this invention has N-fi-phenethyl glycolamide as its essential active ingredient.
Further criteria characterizing the novel properties of the aforesaid compounds is that the hypocholesteremic effect be obtained upon oral administration and that the essential active ingredients be substantially without toxicity and that they exert little or no effect in other pharmacological areas at dosage levels consistent with good hypocholesteremic activity.
The compounds of this invention are active, however, when administered orally, rectally, or parenterally.
The active ingredients are obtained as distillable oils or low melting solids and are somewhat soluble in water, but for therapeutic use, they are preferably incorporated in suitable pharmaceutical carriers and in use, the compounds are employed in the recommended dosage of 100-1200 mg./day, preferably in doses of 150-300 mg, two or four times a day. Thus, in preparing tablets, sustained-release capsules, capsules, elixers, suppositories, or other dosage forms with pharmaceutical carriers, the formulation should preferably contain 50-500 mg. of active drug per dosage unit.
3,193,453 Patented July 6, 1965 As more fully illustrative of the pharmacological standards of active ingredients typifying this invention, there is described below a variety of tests with N- (B-phen'ethyl) glycolamide in greater detail, to indicate its relative absence of other pharmacological effects and its substantial absence of toxicity.
Acute toxicity data are shown in Table II.
TABLE II.ACUTE TOXICITY OF N-(B- PHENETHY L) GLYCOLAMIDE Species Route LD50 Mensa Oral 1, 500 Guinea pig Oral 1, 350 Bath Oral 2, 450
Deaths were recorded for a week after a single administration.
The drug was inactive in the following pharmacological tests (30 and 60 mg./kg. orally): anticonvulsant, antitremorine, muscle relaxant, bronchodilator. No central nervous excitatory or depressant activity was observed up to mg/kg. S.C. and 60 mg./kg. orally. It had no local anesthetic action on the guinea pig eye at 20 mg./ml.
Injected intravenously to anesthetized dogs at 5 mg./kg., N-(fi-phenethyl)glycolamide was without significant effect on blood pressure, heart rate, or the rate of respiration. It did not modify the response to subsequent injections of adrenaline, acetylcholine or histamine.
Addition of the drug to isolated guinea pig ileum and rat uterus at 40 ,ug. per ml. had no effect on the contraction or on the response of the tissues to histamine and acetylcholine.
The bromsulfalein test and prothrombin time were normal after 3 days administration.
The compound had no analgesic effect on testing as high as 250 mg./kg. subcutaneously, but at these substantially higher doses and upon S.C. injection, it had anticonvulsant activity.
In general, at doses consistent with good hypocholesteremic effect, no other pharmacological effects were noted.
Upon oral administration to rats for 6 weeks, at 30,
and 600 mg./kg. (10 rats per group) there were no deaths at 30 and 150 mg./kg. levels whereas at the 600 rug/kg. group, one death after 16 days on test was noted. No observed changes due to drug treatment were noted during this period of feeding the drug and no significant differences in body weight over that obtained with the controls. The hematological studies at the end of the test showed no significant difference in red and white counts or in hemoglobin levels over that noted with the controls. Blood chemistry studies indicated no significant change in blood glucose, urea nitrogen, or serum protein levels when compared to the controls. Histological studies on the organs after completion of the chronic toxicity test showed no pathological findings at any of the dosage levels.
Compounds which have this desirable activity can be prepared in various ways. Thus, for the compounds where n=1, the desired route is by reaction of the appropriate amine, RNH with ethyl glycolate as detailed by Shapiro et 211., I. Am. Chem. Soc, 81, 6322 (1959). Alternative procedures involve condensation under reflux of the amine with glycolic acid in Xylene with removal of formed Water by means of a Dean-Stark trap.
The corresponding hydroxyamides where n=2 are obtainable preferably by the reaction of the amine with The following examples reflect the mode of preparation of the essential active ingredients of the present inveiltion asweu as the preparation of typical administerable formulations of said active ingredients but it is to be understood that these examples are given by way of illustration and not by limitation.
Example 1 .N-(fi'-phenethyl) gly colamide A mixture of 126 g. (1.03 mole) of [i-phenethylamine and 96 g. (0.924 mole) of ethyl glycolate was heated under reflux for 22 hours. A Dean-Stark trap was interposed to remove the formed ethanol (theory 54 ml.). When 48 ml. of ethanol had been collected and the internal temperature was 145, the residue was cooled and 270 ml. ethyl acetateaddedI On standing, the product (107.5 g.) separated, M.P. 61-62 addition of hexane to the mother liquor yielded an additional 27 g., M.P. 65 70". The combined yield (134.5 g.) was stirred with '180 ml. water and the precipitate washed with ice Water to give 96 g., M.P. 77-78 (58% which on recrystallization (acetone-hexane) gave 89.7 g. of product, M.P. 77-78.
In a similar manner, employing the appropriate amine, there is obtained N-(n-amyl)glycolamide, N-(i-amyl) glycolamide, N- (n-butyl glycolamide.
Example -(lt-amyl) -fl-hydroxypropionamide To a solution of 7.2g. (0.1 mole) of propiolactone in 50 ml. of water cooled to 0-5, there was added 8.7 g. (0.1 mole) n-amylamine over 15 minutes with stirring. Water was removed by vacuum distillation. The residue was stirred with hexane, the hexane removed and the residue (11.9 g.) distilled to give 6.2 g., 13.1 l30-132 (0.5 mm.), n 1.4714.
Analysis.Calcd. for C H NO C, 60.3; H, 10.8; N, 8.8. Found: C, 60.1; H, 10.4; N, 9.1.
In a similar manner using the appropriate amine, there solid was recrystallized (acetone-hexane) to give 9.2 g.
(59%) of product, M.P. 57-59". v
Analysis.-Calcd. for C H NO C, 70.6; H, 8.7; N,
6.3. Found: C, 71.0; H, 8.8; N, 6.2.
Example 6 .-N ,G-phnethyl -p-hydr0xy propionamide To a cooled solution (5 aqueous) of 12.1 g. (0.1 mole) of B-phenethylamine, was added dropwise over 15 minutes 7.2 g. (0.1 mole) of freshly distilled 18-propiolactone. After removal of water by vacuum distillation, the residue was distilled to give 10.7 g.,B.P. 180 (.08
is obtained N-(i-amyl)-,8-hydroxypropionamide, and N- Y i-butyl -fi-hydroxypropionamide.
Exdmple 3 .N- (n-dmyl -3-hydroxyvaleramide Exam pl 0 4 .N -(n-amy l -y-hydroxybutyramide A mixture of 8.6 g. (0.1 mole) of 'y-butyrolactone and 8.7 g. (0.1 mole) of n-amylamine was maintained at 20 over '9 days. Upon addition of pentane and ethyl acetate and cooling to 5 there'was obtained 13.0 g. of
product, M.P. 34-36", which on recrystallization (acetone-hexane) gave 9.2 g. (53%) of pure product, M.P. 35. 7 Analysis. ,Calcd. for C H NO 'C, 62.4; H, 11.1; N, 8.1. Found: C, 62.4; H, 11.4; N, 8.0.
In asimila'r manner using the appropriate amine, there is obtained N-(,G-phenethyl)-'y-hydroxybutyramide, N-(iamyl)-'y-hydroxybutyramide, N (i-butyl) 7 hyd-roxybutyramide, N-(n-butyl)-' -hydroxybutyramide.
, Example 5 .-N-( ,S-phenethyl -6-hydr0xyvaleramicie A mixturepf 7.0 g. (0. 7 mole) of E-valerolactone and 8.5g. (07 mole) of .fi-phenethylamine was maintained at 6070 for 38 hours. When cool, the resultant Analysis.-Calcd. for C1 H NO N, 7.3. Found: N, 7.0. 9
Example 7.-Tdb let formation A granulation is prepared of Lactose V parts 74 Starch do 26 Water, a sufiicient quantity.
The granulation is dried and screened.
. G. Hydroxyamide Lactose granulation Magnesium stearate 5 are mixed well together and compressed intotablets weighing 250 mg. (diameter 9 mm.) and containing 100 mg. of hydroxyamide.
Other typical formulations include coated tablets, capsules, and sustained-release capsules containing 50500 mg; of active ingredient per unit dose.
Example 8.-Elixers An enxer is prepared containing per liter Distilled water to 1000 ml.
The hydroxyarnide is dissolved in about two-thirds of the ethanol and the glyoerinand sorbitol are added. The benzoic acid and flavors are dissolved in the balance of the alcohol and combined with the first solution. The saccharin and Sucaryl are dissolved in a small amount of the water and coloring agent dissolved therein.' The aqueous solution is then added to the alcohol. solution, the balance of the water 'is added to bring the volume to 1 liter and after mixing and filtering an eli'xe'r is obtained containing ,20 mg. of the hydroxy-amide per ml. A unit dose of 15 m1. (1 tablespoon) thus contains mg. of the hydroxyamide. 7
Among the additional formulations, which are readily preparable by familiar procedures, are suppositories weighing about 3 g. containing 1503'00 mg. of hydroxyamide. v In the foregoing Examples7 and 8,'it will be understood that any of the hydroxyamides herein characterized as the essential active ingredients may be used, or that a mixture of these amides can be substituted as the active component, and that the amounts of active component can be suitably varied within the range of 50 to 500 rug, and preferably 100 to 400 mg; per dosage unit. In addition, other therapeutic agents may be added to these formulations if so desired Various changes and modifications inthe procedures for preparing these hypocholesteremic hydroxyamides and lncorporating the same into therapeutic compositions will occur to those skilled in the art, and to the extent that such changes and modifications are embraced by the appended claims, it is to be understood that they constitute part of this invention.
Having described our invention, what we claim as new and desire to secure by Letters Patent is:
1. A method for lowering cholesterol levels which comprises administering to an animal a composition containing as an essential active ingredient a compound conssting of hydroxyamides having the following formula H H(0H)n i1 IR wherein n is an integer from 1-4, and R is selected from the group consisting of C -C alkyl and fl-ph-enethyl, said administration being in amounts sufiicient to substantially reduce the cholesterol level of the blood of the hypercholesteremic animal.
2. A method for lowering cholesterol levels as defined in claim 1 wherein the essential active ingredient is N-fifl-phenethyl glycolamide.
3. A method for lowering cholesterol levels as defined in claim 1 wherein the essential active ingredient is N-fiphenethyl-fi-hydroxypropionamide.
4. A method for lowering cholesterol levels as defined 6 in claim 1 wherein the essential active ingredient is N-B- phenethyl-fi-hydroxyvaleramide.
5. A method for lowering cholesterol levels as defined in claim 1 wherein the essential active ingredient is N-n-amyl-y-hydroxybutyramide.
6. A method for lowering cholesterol levels as defined in claim 1 wherein the essential active ingredient is N-namyl-fi-hydroxyvaleramide.
References Cited by the Examiner UNITED STATES PATENTS 2,490,756 12/49 Kenyon et a1. 260-561 2,923,738 2/60 Williams et a1. 260-561 2,937,117 5/60 Cottet et al 167-65 2,941,002 6/ Ehrhart et al. 260562 2,980,585 4/61 Stambul 167-65 FOREIGN PATENTS 1,064,049 8/59 Germany.
OTHER REFERENCES Shapiro, JACS, vol 81, 1959, pp. 6322-29. JULIAN S. LEVITT, Primary Examiner.
IRVING MARCUS, FRANK CACCIAPAGLIA, JR.,
LEWIS GOTTS, Examiners.
Claims (1)
1. A METHOD FOR LOWERING CHOLESTEROL LEVELS WHICH COMPRISES ADMINISTERING TO AN ANIMAL A COMPOSTION CONTAINING AS AN ESSENTIAL ACTIVE INGREDIENT A COMPOUND CONSISTING OF HYDROZYAMIDES HAVING THE FORLLOWING FORMUAL
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US123435A US3193458A (en) | 1961-07-12 | 1961-07-12 | Method of lowering blood cholesterol level |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US123435A US3193458A (en) | 1961-07-12 | 1961-07-12 | Method of lowering blood cholesterol level |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3193458A true US3193458A (en) | 1965-07-06 |
Family
ID=22408671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US123435A Expired - Lifetime US3193458A (en) | 1961-07-12 | 1961-07-12 | Method of lowering blood cholesterol level |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3193458A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3728459A (en) * | 1970-07-13 | 1973-04-17 | Sumitomo Chemical Co | Certain n-substituted octadecadienoic acid amides used to reduce cholesteral levels |
| US3741999A (en) * | 1964-04-28 | 1973-06-26 | Sumitomo Chemical Co | N-substituted amides of natural fatty acids |
| JPS4892327A (en) * | 1972-03-16 | 1973-11-30 | ||
| EP1383778A2 (en) * | 2001-01-30 | 2004-01-28 | University Of Virginia Patent Foundation | Agonists and antagonists of sphingosine-1-phosphate receptors |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2490756A (en) * | 1947-11-22 | 1949-12-06 | Eastman Kodak Co | N-alkenyl lactamides |
| DE1064049B (en) * | 1956-12-08 | 1959-08-27 | Hoechst Ag | Process for the preparation of N-substituted beta-oxybuttersureamides with analgesic activity |
| US2923738A (en) * | 1958-05-08 | 1960-02-02 | Gen Aniline & Film Corp | Addition products of n-alkyl-gamma-hydroxycarboxylic acid amides and alkanolamines |
| US2937117A (en) * | 1953-06-19 | 1960-05-17 | Chimie Atomistique | Process for lowering high blood cholesterol levels |
| US2941002A (en) * | 1956-11-06 | 1960-06-14 | Hoechst Ag | Beta-hydroxy carboxylic acid amides substituted at the nitrogen atom |
| US2980585A (en) * | 1958-09-11 | 1961-04-18 | Stambul Rae | Controlling the blood cholesterol level by administration of diiodotyrosine polypeptide |
-
1961
- 1961-07-12 US US123435A patent/US3193458A/en not_active Expired - Lifetime
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2490756A (en) * | 1947-11-22 | 1949-12-06 | Eastman Kodak Co | N-alkenyl lactamides |
| US2937117A (en) * | 1953-06-19 | 1960-05-17 | Chimie Atomistique | Process for lowering high blood cholesterol levels |
| US2941002A (en) * | 1956-11-06 | 1960-06-14 | Hoechst Ag | Beta-hydroxy carboxylic acid amides substituted at the nitrogen atom |
| DE1064049B (en) * | 1956-12-08 | 1959-08-27 | Hoechst Ag | Process for the preparation of N-substituted beta-oxybuttersureamides with analgesic activity |
| US2923738A (en) * | 1958-05-08 | 1960-02-02 | Gen Aniline & Film Corp | Addition products of n-alkyl-gamma-hydroxycarboxylic acid amides and alkanolamines |
| US2980585A (en) * | 1958-09-11 | 1961-04-18 | Stambul Rae | Controlling the blood cholesterol level by administration of diiodotyrosine polypeptide |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3741999A (en) * | 1964-04-28 | 1973-06-26 | Sumitomo Chemical Co | N-substituted amides of natural fatty acids |
| US3728459A (en) * | 1970-07-13 | 1973-04-17 | Sumitomo Chemical Co | Certain n-substituted octadecadienoic acid amides used to reduce cholesteral levels |
| JPS4892327A (en) * | 1972-03-16 | 1973-11-30 | ||
| EP1383778A2 (en) * | 2001-01-30 | 2004-01-28 | University Of Virginia Patent Foundation | Agonists and antagonists of sphingosine-1-phosphate receptors |
| EP1383778A4 (en) * | 2001-01-30 | 2005-03-09 | Univ Virginia | Agonists and antagonists of sphingosine-1-phosphate receptors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69807349T2 (en) | THYROXIN ANALOGA WITHOUT SIGNIFICANT HORMONAL EFFECT FOR THE TREATMENT OF Vicious TUMORS | |
| US3809714A (en) | Novel ester of ((methylamino)methyl) benzyl alcohol | |
| JPS62240619A (en) | Anticancer | |
| JPS6144844B2 (en) | ||
| JPH09501653A (en) | Pharmaceutical composition | |
| US3932638A (en) | Compositions and methods for wound healing | |
| IL30782A (en) | Amino guanidines | |
| US3483221A (en) | 1 - (isopropylamino)-2-hydroxy-3-(alkenyloxyphenoxy) - propanes and the salts thereof | |
| US3193458A (en) | Method of lowering blood cholesterol level | |
| US5149688A (en) | Methods, compounds, and compositions for immunosuppression | |
| US3487155A (en) | Substituted estradiol alkyl ethers | |
| JPS60120995A (en) | Production of new amino acid derivative | |
| EP1662875A2 (en) | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders | |
| US6664394B2 (en) | Derivatives of butyric acid | |
| JPH0723387B2 (en) | Piperazinecarboxylic acid, method for producing the same, and pharmaceutical composition containing the same | |
| Brown et al. | Pharmacological studies on the antispasmodic, β‐diethylaminoethyl 1‐cyclohexylcyclo‐hexanecarboxylate hydrochloride | |
| JPH06211660A (en) | Nerve growth factor-production promoter | |
| Farmer et al. | Comparative beta-adrenoceptive stimulant properties of salbutamol (AH 3365), orciprenaline and soterenol (MJ 1992). | |
| US5859046A (en) | Biologically active oreido derivatives useful in the treatment of multiple sclerosis | |
| JPH03141284A (en) | 4-(2-methyl-2-hydroxypropylamino)-5, 6-dihydrocheno-(2, 3-b)thiopyran-2-sulfonamide-7, 7-dioxide | |
| US6166074A (en) | Pharmaceutical compositions | |
| EP0121856A2 (en) | Use of pyrazolone derivatives against the growth of tumour cells and their metastases, medicaments therefor and their preparation | |
| JPS6119632B2 (en) | ||
| JPH02304058A (en) | Xanthocillin x monomethyl ether derivative and antineoplastic agent | |
| US3108045A (en) | Metal chelates of oxazolidinones as central nervous system stimulants |